ArticleThe Linacre quarterly2021
Charting a Course toward a New Vaccine Strategy.
Article in The Linacre quarterly, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There has been a long-simmering disquiet in Catholic circles regarding the use cell lines derived from aborted fetal tissue. This concern has exploded into the public consciousness given the use of questionable cell lines in the development and/or testing of the current COVID-19 vaccines, and the debate within the Church over the permissibility of using these vaccines. The history of cell culture and how the biological community came to rely on HEK293 fetal cell lines is explored, as is the way forward, moving the biotech industry away from ethically problematic cells and toward the development of more ethically sourced cell lines. The role of the Church in leading the way forward and the acceptable use of medicines utilizing HEK293 cell lines are all explored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.